SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for s ...
REFINE data showed patients with resistant and refractory migraine have a higher burden of comorbidities than those with nonresistant and nonrefractory migraine.